compound 31 [PMID: 31259550]   

GtoPdb Ligand ID: 10417

Compound class: Synthetic organic
Comment: Compound 31 is a selective antagonist of CCR4 [1].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 90.86
Molecular weight 510.17
XLogP 4.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES OCC1CCCN1C1CC=C(CC1C)c1cnc2c(n1)n(nc2C#N)C(c1ccc(cc1Cl)Cl)C
Isomeric SMILES OC[C@@H]1CCCN1[C@H]1CC=C(C[C@H]1C)c1cnc2c(n1)n(nc2C#N)[C@@H](c1ccc(cc1Cl)Cl)C
InChI InChI=1S/C26H28Cl2N6O/c1-15-10-17(5-8-24(15)33-9-3-4-19(33)14-35)23-13-30-25-22(12-29)32-34(26(25)31-23)16(2)20-7-6-18(27)11-21(20)28/h5-7,11,13,15-16,19,24,35H,3-4,8-10,14H2,1-2H3/t15-,16-,19+,24+/m1/s1
InChI Key KQZLRWGGWXJPOS-NLFPWZOASA-N
Immunopharmacology Comments
Compound 31 was designed to examine the potential of small molecule CCR4 antagonists as immuno-oncology drugs. It was found to reduce trafficking of Treg cells to the tumour microenvironment but did not inhibit their migration to the spleen, which suggests that compound 31 may not disrupt crucial immune functions of Treg in healthy, non-target tissues [1].